Motor neuron growth factors
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
The last 5 years have witnessed a great outgrowth in the number of clinical trials testing neuronal growth factors as potential treatments in ALS. These attempts to prevent motor neuron degeneration in ALS with the use of growth factors have their basis in the profound abilities of these molecules to affect motor neuron survival in experimental animals during early development and into maturity. Recent advances in molecular biology have led to the identification of a large number of new potential motor neuron growth factors Table 1, as well as insights into the molecular mechanisms regulating motor neuron death after growth factor deprivation. A major challenge in the field is now to select those growth factors that are the most promising for future ALS trials either alone or in combination therapy.
- In this window
- In a new window
Growth factors regulate motor neuron survival in vivo.
Two members of the prototypical family of nerve growth factors, the neurotrophins, are powerful modulators of motor neuron survival during development and into adulthood. The neurotrophin family in mammals comprises four members, including nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and neurotrophin-4 (NT-4), molecules that share a significant degree of sequence homology. [1] An early indicator that one or more members of this neurotrophin growth factor family might affect motor neurons derived from experiments performed by Yan and colleagues. [2] These investigators demonstrated that motor neurons have the ability to retrogradely transport members of the neurotrophin family, including BDNF and NT-3, after these molecules have been injected into peripheral muscle. This experiment provided evidence that motor neurons express receptors for neurotrophins and might, in fact, respond to them. Localization studies have also demonstrated that skeletal muscle normally synthesizes neurotrophins (BDNF, NT-3, and NT-4) during the period of motor neuron innervation, during the maturation of synapse formation, and into adulthood. [3,4] …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Dennis Bourdette and Dr. Lindsey Wooliscroft
► Watch
Related Articles
- No related articles found.
Alert Me
Recommended articles
-
Clinical Trials and Future Research
Drug combination treatment in patients with ALSCurrent status and future directionsHiroshi Mitsumoto, Richard K. Olney et al.Neurology, October 01, 1996 -
Articles
New approaches to the treatment of ALSRobert G. Miller, Robert Sufit et al.Neurology, April 01, 1997 -
Articles
Neuroprotection and repair by neurotrophic and gliotrophic factors in multiple sclerosisJeffrey A. Loeb et al.Neurology, June 04, 2007 -
Articles
Dual role of inflammation in CNS diseaseReinhard Hohlfeld, Martin Kerschensteiner, Edgar Meinl et al.Neurology, June 04, 2007